Data suggest major uncertainties remain about impact of treatment for gender-related distress

Major uncertainties remain about the impact of puberty blockers and gender-affirming hormone therapy on children and young people with gender-related distress (gender dysphoria), making it impossible to determine conclusively whether they help or harm, finds two pooled data analyses of the available evidence, published online in the Archives of Disease in Childhood.

Study finds NSAID allergies among stroke patients are mislabeled in 80% of cases

A recent study conducted by the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) found that mislabeled NSAID (Non-Steroidal Anti-Inflammatory Drug) allergies for stroke patients hinders the use of effective medications for them, leading to poorer treatment outcomes. It also revealed that when stroke survivors with NSAID allergy labels underwent testing, 80% were found to be mislabeled.

Researchers investigate relationship between cognitive functioning and socioeconomic factors

To remain mentally fit for as long as possible in old age, it is important to understand which risk factors could impact cognitive functioning already early in life. Scientists led by the German Centre for Neurodegenerative Diseases (DZNE) in Greifswald and the Institute of Social Medicine, Occupational Medicine and Public Health (ISAP) at Leipzig University have used data from the German National Cohort (NAKO) to investigate the relationship between aspects of socioeconomic inequality and cognitive functioning. The work is published in the journal Aging, Neuropsychology, and Cognition.

Metronomic chemotherapy: A promising approach for pediatric neuroblastoma

Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease. Despite advances in treatment, survival rates for high-risk and relapsed/refractory neuroblastoma remain dismal, and options like autologous stem cell transplantation and immunotherapy are frequently unavailable in low- and middle-income countries.